JP2017520527A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520527A5
JP2017520527A5 JP2016567824A JP2016567824A JP2017520527A5 JP 2017520527 A5 JP2017520527 A5 JP 2017520527A5 JP 2016567824 A JP2016567824 A JP 2016567824A JP 2016567824 A JP2016567824 A JP 2016567824A JP 2017520527 A5 JP2017520527 A5 JP 2017520527A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
compound
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520527A (ja
JP6625064B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053609 external-priority patent/WO2015173786A1/en
Publication of JP2017520527A publication Critical patent/JP2017520527A/ja
Publication of JP2017520527A5 publication Critical patent/JP2017520527A5/ja
Application granted granted Critical
Publication of JP6625064B2 publication Critical patent/JP6625064B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567824A 2014-05-15 2015-05-15 眼障害を治療かつ診断するための組成物および方法 Active JP6625064B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461993915P 2014-05-15 2014-05-15
US61/993,915 2014-05-15
US201462064344P 2014-10-15 2014-10-15
US62/064,344 2014-10-15
US201462076162P 2014-11-06 2014-11-06
US62/076,162 2014-11-06
US201562157773P 2015-05-06 2015-05-06
US62/157,773 2015-05-06
PCT/IB2015/053609 WO2015173786A1 (en) 2014-05-15 2015-05-15 Compositions and methods for treating and diagnosing ocular disorders

Publications (3)

Publication Number Publication Date
JP2017520527A JP2017520527A (ja) 2017-07-27
JP2017520527A5 true JP2017520527A5 (cg-RX-API-DMAC7.html) 2018-06-28
JP6625064B2 JP6625064B2 (ja) 2019-12-25

Family

ID=54479391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567824A Active JP6625064B2 (ja) 2014-05-15 2015-05-15 眼障害を治療かつ診断するための組成物および方法

Country Status (7)

Country Link
US (2) US20170079955A1 (cg-RX-API-DMAC7.html)
EP (1) EP3142664B1 (cg-RX-API-DMAC7.html)
JP (1) JP6625064B2 (cg-RX-API-DMAC7.html)
DK (1) DK3142664T3 (cg-RX-API-DMAC7.html)
ES (1) ES2789849T3 (cg-RX-API-DMAC7.html)
HU (1) HUE049518T2 (cg-RX-API-DMAC7.html)
WO (1) WO2015173786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
CA3040419A1 (en) * 2016-10-13 2018-04-19 Translatum Medicus, Inc. Systems and methods for detection of ocular disease
WO2018119202A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for increasing level of peroxisome proliferator-activated receptor gamma
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
RU2683758C1 (ru) * 2018-06-27 2019-04-01 Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской академии наук" (ФИЦ ИУ РАН) Автоматизированная система анализа ангиографических изображений глазного дна человека
EP3706136A1 (en) * 2019-03-05 2020-09-09 Novartis AG Computerized systems for prediction of geographic atrophy progression using deep learning applied to clinical imaging
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
RU196414U1 (ru) * 2019-12-23 2020-02-28 Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской Академии Наук" Анализатор ангиографических изображений глазного дна человека
GB202001336D0 (en) * 2020-01-31 2020-03-18 Imp College Innovations Ltd Methods for measuring gut permeability and gastric emptying rate
WO2023200766A1 (en) * 2022-04-14 2023-10-19 Belite Bio, Inc Methods, compositions and systems for evaluation of visual function
EP4662203A1 (en) * 2023-02-10 2025-12-17 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2005108431A1 (en) * 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
US8835481B2 (en) * 2008-03-07 2014-09-16 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
EP2844250B1 (en) * 2012-05-01 2017-11-08 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases

Similar Documents

Publication Publication Date Title
JP2017520527A5 (cg-RX-API-DMAC7.html)
JP7475395B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
RU2014123472A (ru) Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней
NZ610230A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
RU2015117536A (ru) Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний
JP2008538215A5 (cg-RX-API-DMAC7.html)
JP2016519680A5 (cg-RX-API-DMAC7.html)
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−2アドレナリンアゴニスト
JP2015025011A5 (cg-RX-API-DMAC7.html)
TW201136915A (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
JP2014533274A5 (cg-RX-API-DMAC7.html)
JP2014506582A5 (cg-RX-API-DMAC7.html)
JP2017519020A5 (cg-RX-API-DMAC7.html)
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN106604730A (zh) 角膜厚度调节剂
JP2007527417A5 (cg-RX-API-DMAC7.html)
KR20140008303A (ko) 안구 혈관 질환의 치료를 위한 투여 요법
JP2013540791A5 (cg-RX-API-DMAC7.html)
CN110114066B (zh) 含沙丁胺醇的眼科药物
WO2016172205A1 (en) Managing ebola viral infections
RU2020119228A (ru) Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи
JP2021138710A5 (cg-RX-API-DMAC7.html)
JP2020511437A5 (cg-RX-API-DMAC7.html)
JP2011527286A5 (cg-RX-API-DMAC7.html)